Case Reports

Case Reports

Case Report
Abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer
Oronsky B, Larson C, Reid T, Carter C.
Journal of Investigative Medicine High Impact Case Reports, July 6, 2018.

Case Report
A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet
Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.
J Investig Med High Impact Case Rep. 2018 Mar 7.

Case Report
A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Brzezniak C, Oronsky B, Aggarwal R.
Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.

Case Report
RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.
Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C.
Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

Case Report
A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001.
Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid T, Trepel J, Abrouk N, Larson C, Oronsky A, Lybeck H, Day R, Carter C.
Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

Case Report
Conversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the epi-immunotherapeutic RRx-001: A case report.
Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim M, Brown J, Reid T, Larson C, Oronsky A, Day R, Degesys A, Carter C.
Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

Case Report
Partial response in an RRx-001 primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid T, Brzezniak C.
Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

Case Report
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.
Respir Med Case Rep. 2016 Apr 24;18:62-5.

Case Report
Pulmonary tumor thrombotic microangiopathy: A new paraneoplastic syndrome?
Carter C, Scicinski J, Lybeck H, Oronsky B.
Case Rep Oncol. 2016 Apr 23;9(1):246-8.

Case Report
Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A TITE-CRM phase I/II clinical trial
Kim M, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter C, Oronsky A, Knox S, Caroen S, Oronsky B, Scicinski J, Lawrence T, Lao C.
Transl Oncol. 2016 Apr;9(2):108-13.

Case Report
Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
Kim M, Parmar H, Cao Y, Knox S, Oronsky B, Scicinski J, Lawrence T, Lao C.
Neuro Oncol. 2016 Mar;18(3):455-6.

Case Report
RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Kim M, Oronsky A, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.
Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

Case Report
Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001
Carter C, Schmitz B, Peterson P, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid T, Cabrales P, Brzezniak C.
Case Rep Oncol. 2016 Mar 10;9(1):164-70.

Case Report
Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.
Case Rep Oncol. 2016 Jan 28;9(1):62-7.

Case Report
The case of a zebra that was misdiagnosed as a horse: Pulmonary tumor thrombotic microangiopathy, a new paraneoplastic syndrome, mimicking PD-1-Induced pneumonitis
Carter C, Browning R, Oronsky B, Scicinski J, Brzezniak C.
Case Rep Oncol. 2016 Jan 27;9(1):68-75.

Case Report
RRx-001-induced tumor necrosis and immune cell Infiltration in an EGFR mutation-positive NSCLC with resistance to EGFR tyrosine kinase inhibitors: A case report
Brzezniak C, Schmitz B, Peterson P, Degesys A, Oronsky B, Scicinski J, Caroen S, Carter C.
Case Rep Oncol. 2016 Jan 15;9(1):45-50.

Case Report
Flushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor
Carter C, Degesys A, Oronsky B, Scicinski J, Caroen S, Oronsky A, Reid T, Cabrales P, Roswarski J.
Case Rep Oncol. 2015 Oct 30;8(3):461-5.

Case Report
Dysphonia after bevacizumab rechallenge: A case report.
Carter C, Caroen S, Oronsky A, Oronsky B.
Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

Case Report
Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients
Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J.
Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382.